News

CBB Member Emmanuel Ho and collaborators from the University of Manitoba have created a new therapy to combat deadly bacteria infecting hospital patients worldwide.

The new therapy is a biocide able to target antibiotic-defiant bacteria such as Methicillin resistant Staphylococcus aureus (MRSA). The team's goal was to find a way around the superbug's defences, using a new approach based on material science.

Karly Smith, 3A biomedical engineering studen at UW and student of CBB member George Shaker, has qualified to the Top 75 in Canada for NSERC's Science, Action! Competition.

CBB member Edith Law is actively working on CrowdEEG, an innovative tool for medical time series data.

Thomas Willett, and co-applicants including Maud Gorbet and Alex El-Warrak, have been awarded $665,552 over four years from Canadian institutes of health Research (CIHR). The award was granted for their project titled "Bone-mimetic nanocomposite biomaterials for critically-sized skeletal defect reconstruction."

CBB researcher and professor of computing science Pascal Poupart discusses the use of AI to create a bridge between academia and business.

Jennifer Boger, Shi Cao and collaborators are investigating new ways to provide individualized exercise opportunities for older adults and persons living with dementia.

Andrew Doxey and colleagues have discovered a new kind of botox.

A new source of the botulinum neurotoxin was discovered in a strain of animal gut bacteria, known as Enterococcus faecium. Over the past 20 years, there have been a growing number of therapeutic applications for botulinum toxin type A, known as botox, including treatment for migraines, leaky bladders, excessive sweating, and cardiac conditions.

Mohammad Kohandel, Sivbal Sivaloganathan and colleagues have discovered that applied mathematics can be used as a tool in predicting the genesis and evolution of different types of cancers. 

The study uses evolutionary dynamics, a form of mathematical analysis, to look at how mutations evolve in stem and non-stem cells in colorectal and intestinal cancers.

Marianna Foldvari received an award for Outstanding Lifetime Achievements in Nanoscience from NanoOntario, an organization that represents the province’s nanotechnology community. She has also been appointed a fellow of the prestigious American Association of Pharmaceutical Sciences (AAPS).  Dr. Foldvari is a global leader in non-invasive gene therapy and nanomedicine-based large drug molecule delivery.

Congratulations!